Skip to content

DiaNow Feasibility of smaRt pAtient ManagemEnt in Diabetes mellitus Type 2 (DiaNow-FRAMED): a multicenter prospective randomized controlled cohort study

DiaNow Feasibility of smaRt pAtient ManagemEnt in Diabetes mellitus Type 2 (DiaNow-FRAMED): a multicenter prospective randomized controlled cohort study - DiaNow-FRAMED

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00036560
Enrollment
80
Registered
2025-04-01
Start date
2024-05-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11

Interventions

Group 1: Usual care for three months (baseline visit and follow-up visit) Group 2: DiaNow eHealth App for three months (baseline visit and follow-up visit)

Sponsors

Universitätsklinik Aachen, AöR
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus or anti-diabetic treatment: HbA1c = 7.5 % (= 58 mmol/mol) or < 10.0% (< 86 mmol/mol) • Ability to give consent • Adequate understanding of the German language

Exclusion criteria

Exclusion criteria: Other diabetes mellitus entities (T1DM, LADA, MODY, NODAT, diabetes after steroids or other endocrine diseases, etc.) • HbA1c = 10.0% (=86 mmol/mol) • No technical know-how in the field of smartphone/tablet Uncontrolled or serious illness or any medical or surgical condition (e.g., tumor disease, terminal cardiac failure, severe pulmonary disease, liver cirrhosis, post-organ transplant) that may either interfere with participation in the clinical trial and/or place the subject (in the judgment of the investigator [or delegate]) at significant risk if the subject participates in the clinical trial. • A known underlying disease or surgical, physical, or medical condition (e.g., tumor disease, terminal heart failure, severe lung disease, liver cirrhosis, post-organ transplant) that, in the opinion of the investigator (or delegate), could affect the interpretation of the clinical trial results Participation in a clinical intervention study with comparable endpoints and/or interventions for the treatment of type 2 diabetes (e.g. Vivora Coaching, mySugarApp) Pregnancy Insufficient language skills Inmates or patients under custodial care

Design outcomes

Primary

MeasureTime frame
Change between baseline and 12 weeks of HbA1c levels

Secondary

MeasureTime frame
Change in quality of life (diabetes-associated problem and distress (PAID))

Countries

Germany

Contacts

Public ContactJulia Brandts

Koordinierungszentrum für Kardiologische Studien (KKS) der Uniklinik RWTH Aachen

jbrandts@ukaachen.de+49 (0) 241 80-35227

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026